Breast Cancer

The National Cancer Institute (NCI) has begun the largest, most comprehensive effort to identify genetic risk factors for two major cancers, a 3-year initiative aimed at deciphering which genetic alterations put people at increased risk of developing breast and prostate cancer.

Biopsy remains the gold standard for diagnosing breast cancer in women whose mammograms or physical exams yield abnormal findings, according to a new federal report

Two studies presented at the 28th Annual San Antonio Breast Cancer Symposium suggest researchers are getting closer to developing patient-specific prognostic assays for breast cancer recurrence.

Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS).

Marked reductions in breast cancer recurrence were achieved with a shorter standard adjuvant chemotherapy regimen, augmented by weekly doses of paclitaxel, in a study by the Spanish Group for Breast Cancer Research, the GEICAM 9906 trial, presented at the 28th Annual San Antonio Breast Cancer Symposium (abstract 39).

The first comprehensive assessment of cancer care quality in the United States indicates adherence to recommended care for patients with breast or colorectal cancer is excellent overall, but specific areas need improvement. Overall, breast cancer patients received 86% of generally recommended care, based on 36 quality-care measures. Patients with colorectal cancer received 78% of generally recommended care, based on 25 quality-care measures.

Adjuvant dose-dense chemotherapy for breast cancer was validated by the updated results of Intergroup C9741, most notably in women with estrogen-receptor (ER)-negative disease.

Nine weeks of trastuzumab (Herceptin) given concurrently with single-agent docetaxel (Taxotere) or vinorelbine (Navelbine) prior to combination chemotherapy improves survival in HER2-positive breast cancer patients, compared with no trastuzumab, with the docetaxel regimen having a slight advantage over vinorelbine.

The risk for a new cancer in the unaffected breast substantially increases in women diagnosed with unilateral, hereditary (non-BRCA) breast cancer, according to a new study. Published in the March 15, 2006, issue of Cancer, the study reveals that women under age 50 diagnosed with hereditary (non-BRCA) breast cancer are at significantly greater risk for developing cancer in the other breast. Adjuvant hormonal therapy, however, reduces contralateral breast cancer risk.

Investigators at Johns Hopkins University Kimmel Comprehensive Cancer Center have begun phase I studies of intraductal chemotherapy in women with breast cancer scheduled for mastectomy. The chemotherapy agent is injected via hair-thin catheters into the milk ducts.

In patients with noninflammatory locally advanced breast cancer (LABC), hyperfractionated radiation of the chest wall does not improve clinical outcomes relative to conventional radiation, according to long-term results of a trial presented at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 2008).

Discussing decades of work in developing trastuzumab (Herceptin), and looking to the future based on techniques that led to the understanding of HER2/neu, Dennis J. Slamon, MD, PhD, presented the William L. McGuire Memorial Lecture at the 28th Annual San Antonio Breast Cancer Symposium. Dr. Slamon is director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center.

Surgical biopsy for the initial evaluation of breast lesions should be discouraged, according to Stephen D. Edge, MD, of Roswell Park Cancer Institute, Buffalo, New York, who presented a study comparing biopsy techniques at the 28th Annual San Antonio Breast Cancer Symposium .

Use of adjuvant chemotherapy with docetaxel (Taxotere) and cyclophosphamide (TC) is associated with a 33% improvement in disease-free survival and trend for improvement in overall survival in early-stage breast cancer, compared with the standard doxorubicin (Adriamycin)/cyclophosphamide (AC) regimen, according to the final analysis of a study from US Oncology Research, Houston

Femara (letrozole, Novartis) has received FDA approval for use in treating early breast cancer in postmenopausal women following surgery. The agency based its approval on findings from the BIG I-98 study, the only trial designed to compare the safety and efficacy of Femara vs tamoxifen when used as adjuvant therapy in postmenopausal women with hormone-receptor-positive early disease.

Bevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), conferred additional benefit to paclitaxel when the combination was used as first-line therapy in locally recurrent and metastatic breast cancer patients in the Eastern Cooperative Oncology Group (ECOG) phase III E2100 study.

When breast cancer recurs locally after breast-conserving therapy, prognosis is better for patients whose recurrence is "elsewhere" in the breast than for those whose recurrence is in the primary tumor bed, new research shows. However, regardless of the type, control of the local recurrence is the most significant predictor of subsequent distant metastasis and survival.

The first interim results from the BCIRG 006 phase III trial showed that trastuzumab (Herceptin) combined with docetaxel (Taxotere)-based regimens significantly improved disease-free survival (DFS) in early HER2-positive breast cancer. Genetic studies further delineated a subgroup of patients for whom truly targeted therapy may be applied in the future.

Docetaxel (Taxotere) and paclitaxel (Taxol) produced similar outcomes in the adjuvant treatment of breast cancer in the North American Breast Cancer Intergroup Trial E1199. Joseph Sparano, MD, profesor of medicine, Albert Einstein Cancer Center, Montefiore Medical Center, New York, presented the results as a late-breaking abstract at the 28th Annual San Antonio Breast Cancer Symposium (abstract 48).

Accumulating clinical experience with MammoSite breast brachytherapy is supporting its safety, efficacy, and good cosmetic outcomes, while also providing lessons to improve its use, according to a pair of studies presented at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

Recent clinical studies from the National Cancer Institute (NCI) show that the macrolide analog ixabepilone (BMS-247550) is effective in treating metastatic breast cancer, is less susceptible to resistance than paclitaxel, and is associated with much lower rates of peripheral neuropathy than the taxanes.

Radiation therapy (RT) reduces the risk of breast cancer recurrence even in women with favorable early disease, researchers reported at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 3). Although recurrence was uncommon with combined breast-conserving surgery and hormonal therapy, it was one-half less common when whole-breast radiation therapy was further added to treatment.

The past 2 decades of systemic therapy for breast cancer have beena period of monumental change, in terms of both theory and technology.Adjuvant therapy developed from two strands of research-one insystemic chemotherapy and one in hormonal therapy-both of whichwere aided by the application of higher statistical methodology to clinicaltrials. The agent with the single greatest public health impact inoncology has been tamoxifen, but problems with tamoxifen therapy ledto the development of the aromatase inhibitors, and further researchled to the use of hormonal therapy in a chemopreventive capacity. Theevolution of systemic chemotherapy for breast cancer has been an interplaybetween theory-driven approaches and new agents. By the late1980s, accumulating data revealed that overexpression of HER2 (erbB2)played an important role in a substantial portion of breast cancers,which prompted the development of trastuzumab (Herceptin), an agenttargeting HER2-positive disease. Determining HER2 status proved essentialto assessing patient eligibility for trastuzumab therapy. Decodingof the human genome and application of bioinformatics furtherrevolutionized the possibilities in breast cancer treatment.

After peaking in 1990, the absolutenumber of deaths peryear attributed to breast cancerhas fallen steadily.[1] This declineoccurred despite trends thatwould seem to increase breast cancermortality (population growth, aging,increased obesity) and was mirroredeven in countries lacking routine supportfor mammography. Systemictherapy is at least partly responsiblefor this mortality decline, and in supportof this conclusion the predictedbenefits (based on trials and metaanalyses)have been seen in population-based studies.[2] In this issue ofONCOLOGY, Mina and Sledge providea timely and inspiring review of2 decades of progress in systemic therapyfor breast cancer. This leads toseveral questions, including: How didwe get here and what is next?

Based on their initial experience with 3D digital breast tomosynthesis, radiologists at Dartmouth Hitchcock Medical Center and Dartmouth Medical School believe the investigational technique "is closer to the truth than standard mammography," Steven Poplack, MD, associate professor of diagnostic radiology and obstetrics and gynecology, said at the 2005 meeting of the Radiological Society of North America (abstract SSG01-05).

Over a 30-year period in the20th century, human flightevolved from the propeller tothe jet engine and then managed tosend us to the moon and back. Thechanges over the past 30 years in ourunderstanding of the biology of breastcancer and its application to treatmentare no less startling. Since 1975, wehave witnessed an astounding evolutionin our strategies to prevent,[1]diagnose,[2] and manage[3] a diseasethat affects the lives of so many in theUnited States[4] and around theworld.[5] These efforts have generatedmany headlines and an occasionalstumble. Nonetheless, they have hada dramatic impact on the lives of millionsof people, and it is hoped thatthe rate of improvement will furtheraccelerate in years to come.

DENVER-Accelerated intensity-modulated radiation therapy (IMRT) of the breast in the prone position is feasible and has only modest acute toxicity in patients who have undergone breast-conserving surgery for breast cancer, according to a report presented at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 1062).

Drs. Perez and Muss provide acomprehensive review of therole of adjuvant chemotherapyin the management of breast cancerpatients. The benefits of anthracyclinevs nonanthracycline regimens are discussed,the taxanes are reviewed indetail, and data regarding dose intensity,dose density, and optimal numberof chemotherapy cycles areexplored. Data on newer agents andbiologic agents also are presented.Debate continues regarding the subsetsof patients who will derive thegreatest benefit from chemotherapyand which regimen is most appropriate.While the review indicates theefficacy of several regimens as definedby randomized clinical trials, itdoes not emphasize patient-specificfactors in determining the optimaltherapy for a given patient.

Improvements in early diagnosisand treatment of breast cancer overthe past few decades have clearlyreduced disease-related mortality. The2000 Oxford Overview published recentlyby the Early Breast Cancer Trialists’Cooperative Group (EBCTCG)highlights some of the widely practicableadjuvant drug treatments thatwere under investigation in the 1980s,and have substantially reduced 5-yearrecurrence rates as well as 15-yearmortality rates.[1] Optimal adjuvanthormone therapy is associated with asubstantial improvement of diseaseoutcomes in hormone receptor–positivewomen. Chemotherapy is alsoassociated with considerable benefitsin women with breast cancer, regardlessof age, stage, or hormone receptorstatus. However, chemotherapy isnot without risks. The treatment isassociated with many adverse eventsthat may significantly affect a patient’squality of life while she is receivingtreatment. Other effects may be longstanding,permanent, and, rarely, lifethreatening.